daily oral glp-1 receptor agonist orforglipron for adults with obesity Foundayo (Orforglipron) for Weight Loss:

Tieu S, et al

Irvine BD

5 days/week (~12 mg/day): ~13 vials 3/week (2 mg): ~12 vials 16 weeks: ~3 vials Insulin Syringes (U-100, 1 mL) Per injection: 1 syringe 8 weeks (5 days/week): ~40 syringes 16 weeks (5 days/week): ~80 syringes Bacteriostatic Water (10 mL bottles) Use ~3.0 mL per 50 mg vial for reconstitution

J Clin Invest 108:467475 Postel-Vinay MC, Tar A, Crosnier H, Broyer M, Rappaport R, Tonshoff B, Mehls O (1991) Plasma growth hormone-binding activity is low in uraemic children

Unlike full-length growth hormone, AOD-9604 does not upregulate IGF-1, does not induce insulin resistance in reported toxicology models, and does not measurably affect linear growth in adult animal models